Cardiotoxicity risk with bortezomib versus lenalidomide for treatment of multiple myeloma: A propensity matched study of 1,790 patients

John C. Reneau; Dennis Asante; Holly van Houten; Lindsey R. Sangaralingham; Francis K. Buadi; Amir Lerman; Joerg Herrmann

doi:10.1002/ajh.24599

Cardiotoxicity risk with bortezomib versus lenalidomide for treatment of multiple myeloma: A propensity matched study of 1,790 patients

John C. Reneau, Dennis Asante, Holly van Houten, Lindsey R. Sangaralingham, Francis K. Buadi, Amir Lerman, Joerg Herrmann

Cardiovascular Medicine

Research output: Contribution to journal › Letter › peer-review

12 Scopus citations

Original language	English (US)
Pages (from-to)	E15-E17
Journal	American journal of hematology
Volume	92
Issue number	2
DOIs	https://doi.org/10.1002/ajh.24599
State	Published - Feb 1 2017

ASJC Scopus subject areas

Hematology

Access to Document

10.1002/ajh.24599

Cite this

@article{9db3123ec48e45799a82e39e5a3668e4,

title = "Cardiotoxicity risk with bortezomib versus lenalidomide for treatment of multiple myeloma: A propensity matched study of 1,790 patients",

author = "Reneau, {John C.} and Dennis Asante and {van Houten}, Holly and Sangaralingham, {Lindsey R.} and Buadi, {Francis K.} and Amir Lerman and Joerg Herrmann",

year = "2017",

month = feb,

day = "1",

doi = "10.1002/ajh.24599",

language = "English (US)",

volume = "92",

pages = "E15--E17",

journal = "American Journal of Hematology",

issn = "0361-8609",

publisher = "Wiley-Liss Inc.",

number = "2",

}

TY - JOUR

T1 - Cardiotoxicity risk with bortezomib versus lenalidomide for treatment of multiple myeloma

T2 - A propensity matched study of 1,790 patients

AU - Reneau, John C.

AU - Asante, Dennis

AU - van Houten, Holly

AU - Sangaralingham, Lindsey R.

AU - Buadi, Francis K.

AU - Lerman, Amir

AU - Herrmann, Joerg

PY - 2017/2/1

Y1 - 2017/2/1

UR - http://www.scopus.com/inward/record.url?scp=85009804178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009804178&partnerID=8YFLogxK

U2 - 10.1002/ajh.24599

DO - 10.1002/ajh.24599

M3 - Letter

C2 - 27813147

AN - SCOPUS:85009804178

SN - 0361-8609

VL - 92

SP - E15-E17

JO - American Journal of Hematology

JF - American Journal of Hematology

IS - 2

ER -

Cardiotoxicity risk with bortezomib versus lenalidomide for treatment of multiple myeloma: A propensity matched study of 1,790 patients

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this